Statistical considerations for the next generation of clinical trials

Seminars in Oncology

Volumn 38, Issue 4, 2011, Pages 598-604

  Wu, Wenting ^a   Shi, Qian ^a   Sargent, Daniel J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; FLUOROPYRIMIDINE; FLUOROURACIL; GEMCITABINE; OXALIPLATIN; SORAFENIB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER RESEARCH; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; COLORECTAL CARCINOMA; DISEASE FREE SURVIVAL; DISEASE MARKER; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; KIDNEY CANCER; MAXIMUM TOLERATED DOSE; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SAMPLE SIZE; STATISTICAL PARAMETERS; STUDY DESIGN;

EID: 79961006796     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.05.014     Document Type: Article

References (38)

1. Piantadosi S. Clinical trials: a methodological perspective. New York: Willey Series in Probability and Statistics; 1997.
2. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19:843-50. (Pubitemid 32119100)
3. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000;18:904-14. (Pubitemid 30106623)
4. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-34. (Pubitemid 36910021)
5. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-81.
6. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-70.
7. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-76.
8. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-34. (Pubitemid 46089673)
9. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699-4707. (Pubitemid 46630933)
10. Dodd LE, Korn EL, Freidlin B, et al. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol. 2008;26:3791-96.
11. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013-19.
12. Bhattacharya S, Fyfe G, Gray RJ, Sargent DJ. Role of sensitivity analysis in assessing progression-free survival in late-stage oncology trials. J Clin Oncol. 2009;27:5958-64.
13. Brogilo KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009;101:1642-9.
14. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin. Oncol. 2009;27:3677-83.
15. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89-95.
16. Shi Q, Sargent DJ. Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. Int J Clin Oncol. 2009;14:102-111.
17. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary endpoint for adjuvant colon cancer studies: individual patient data from 20898 patient on 18 randomized trials. J Clin Oncol. 2005;23:8664-70. (Pubitemid 46211509)
18. Buyse M, Burzykowski T, Carroll K, et al. Progressionfree survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol. 2007;25:5218-24. (Pubitemid 350232253)
19. Burzykowski T, Buyse M, Piccart-Gehart MJ, et al. Evaluation of tumor response, disease control, progressionfree survival, and time to progression as potential surrogate endpoints in metastatic breast cancer. J Clin Oncol. 2008;26:1987-92.
20. Fleming TR, DeMets DL. Surrogate endpoints in clinical trials: are we being misled? Ann Intern Med. 1996;125:605-13.
21. Grimes DA, Schulz KF. Surrogate endpoints in clinical research: hazardous to your health. Obstet Gynecol. 2005;105:1114-18. (Pubitemid 40571032)
22. Manns B, Owen WF, Winkelmayer WC, Devereaux PJ, Tonelli M. Surrogate markers in clinical studies: problems solved or created? Am J Kidney Dis. 2006;48:159-66.
23. Sargent DJ, Shi Q, Yothers G, et al. Adjuvant Colon Cancer Endpoints (ACCENT) Group. Two or three year disease free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trails with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07, and C89803. Eur J Cancer. In press.
24. Burzykowski, T, Molenberghs G, Buyse M, eds. The evaluation of surrogate endpoints (statistics for biology and health). New York: Springer; 2005.
25. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics. 1990;46:33-48. (Pubitemid 20245604)
26. Thall PF, Millikan RE, Mueller P, Lee S. Dose-finding with two agents in phase I oncology trials. Biometrics. 2003;59:487-96. (Pubitemid 37093387)
27. Zhang W, Sargent DJ, Mandrekar S. An adaptive dosefinding design incorporating both toxicity and efficacy. Stat Med. 2006;25:2365-83. (Pubitemid 44057044)
28. Braun TM, Wang SA. A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents. Biometrics. 2010;66:805-12.
29. Tang H, Foster NR, Grothey A, Ansell SM, Goldberg RM, Sargent DJ. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. J Clin Oncol. 2010;28:1936-41.
30. Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy P, Smith MA. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol. 2005;23:7199-206.
31. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep. 1985;69:1375-81. (Pubitemid 16163075)
32. Sargent DJ, Goldberg RM. A flexible design for multiple armed screening trials. Stat Med. 2002;21:625-28.
33. Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A. Biomarkers and surrogate endpoints - the challenge of statistical validation. Nat Rev Clin Oncol. 2010;7:309-17.
34. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101:1446-52.
35. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol. 2009;27:4027-34.
36. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol. 2005;23:2020-27. (Pubitemid 46211382)
37. Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J. Adaptive design in clinical drug development - an executive summary of the PhRMA working group. J Biopharmaceut Stat. 2006;16:275-83.
38. Chang M. Adaptive design theory and implementation using SAS and R. New York: Taylor & Francis Group; 2008.